» Articles » PMID: 38341194

Metabolic and Molecular Imaging in Inflammatory Arthritis

Abstract

It is known that metabolic shifts and tissue remodelling precede the development of visible inflammation and structural organ damage in inflammatory rheumatic diseases such as the inflammatory arthritides. As such, visualising and measuring metabolic tissue activity could be useful to identify biomarkers of disease activity already in a very early phase. Recent advances in imaging have led to the development of so-called 'metabolic imaging' tools that can detect these changes in metabolism in an increasingly accurate manner and non-invasively.Nuclear imaging techniques such as F-D-glucose and fibroblast activation protein inhibitor-labelled positron emission tomography are increasingly used and have yielded impressing results in the visualisation (including whole-body staging) of inflammatory changes in both early and established arthritis. Furthermore, optical imaging-based bedside techniques such as multispectral optoacoustic tomography and fluorescence optical imaging are advancing our understanding of arthritis by identifying intra-articular metabolic changes that correlate with the onset of inflammation with high precision and without the need of ionising radiation.Metabolic imaging holds great potential for improving the management of patients with inflammatory arthritis by contributing to early disease interception and improving diagnostic accuracy, thereby paving the way for a more personalised approach to therapy strategies including preventive strategies. In this narrative review, we discuss state-of-the-art metabolic imaging methods used in the assessment of arthritis and inflammation, and we advocate for more extensive research endeavours to elucidate their full field of application in rheumatology.

Citing Articles

Late-Onset Progressive Osseous Heteroplasia: 2 Unrelated Cases and Use of Positron Emission Tomography for Diagnosis.

Pham M, Mahan J, Shah S, Estes S, Kaler S JCEM Case Rep. 2025; 3(3):luae204.

PMID: 40008392 PMC: 11850303. DOI: 10.1210/jcemcr/luae204.


Unconventional Imaging Methods in Psoriatic Arthritis.

Minopoulou I, Fagni F, Atzinger A, Albach F, Schett G, Kronke G Curr Rheumatol Rep. 2025; 27(1):13.

PMID: 39792226 PMC: 11723843. DOI: 10.1007/s11926-024-01174-5.


Recent advances in nuclear medicine and their role in inflammatory arthritis: focus on the emerging role of FAPI PET/CT.

Schmidkonz C, Kuwert T, Gotz T, Ramming A, Atzinger A Skeletal Radiol. 2024; .

PMID: 39586916 DOI: 10.1007/s00256-024-04834-w.


Emerging Landscape of Models for Assessing Rheumatoid Arthritis Management.

Mishra A, Kumar R, Harilal S, Nigam M, Datta D, Singh S ACS Pharmacol Transl Sci. 2024; 7(8):2280-2305.

PMID: 39144547 PMC: 11320735. DOI: 10.1021/acsptsci.4c00260.

References
1.
Koehm M, Ohrndorf S, Foldenauer A, Rossmanith T, Backhaus M, Werner S . Fluorescence-optical imaging as a promising easy-to-use imaging biomarker to increase early psoriatic arthritis detection in patients with psoriasis: a cross-sectional cohort study with follow-up. RMD Open. 2023; 8(2). PMC: 9730423. DOI: 10.1136/rmdopen-2022-002682. View

2.
Schmidt A, Glimm A, Haugen I, Hoff P, Schmittat G, Burmester G . Detection of subclinical skin manifestation in patients with psoriasis and psoriatic arthritis by fluorescence optical imaging. Arthritis Res Ther. 2020; 22(1):192. PMC: 7433190. DOI: 10.1186/s13075-020-02277-x. View

3.
Puuvuori E, Liggieri F, Velikyan I, Chiodaroli E, Sigfridsson J, Romelin H . PET-CT imaging of pulmonary inflammation using [Ga]Ga-DOTA-TATE. EJNMMI Res. 2022; 12(1):19. PMC: 8994000. DOI: 10.1186/s13550-022-00892-0. View

4.
Raynor W, Jonnakuti V, Zirakchian Zadeh M, Werner T, Cheng G, Zhuang H . Comparison of methods of quantifying global synovial metabolic activity with FDG-PET/CT in rheumatoid arthritis. Int J Rheum Dis. 2019; 22(12):2191-2198. DOI: 10.1111/1756-185X.13730. View

5.
Schmidkonz C, Rauber S, Atzinger A, Agarwal R, Gotz T, Soare A . Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis. 2020; 79(11):1485-1491. DOI: 10.1136/annrheumdis-2020-217408. View